Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

National Prevalence of Multidrug-Resistant Organisms

OCT 28, 2016 | CONTAGION EDITORIAL STAFF


Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses his research on the national prevalence of multidrug-resistant organisms.

Interview Transcript (slightly modified for readability)

“We studied several organisms; we studied multidrug-resistant Enterobacteriaceae, multidrug-resistant Acinetobacter, multidrug-resistant Pseudomonas, [and] ESBL, or extended-spectrum β-lactamase-producing organisms as well. We studied these because, as many of you are familiar with the 2013 CDC Antibiotic Threat Report, these organisms were categorized as urgent or serious threats, and it’s one of the reasons why we really selected these organisms, to get an idea of how much is really out there in the overall healthcare setting.”
 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
Big advances in treatment can